Abstract: The present disclosure provides methods for treating a cancer such as an advanced solid tumor in a subject in need thereof by administering to the subject in need thereof an effective first dose of an IL-12 albumin binding domain (ABD) fusion protein and an effective second dose of the IL-12 ABD fusion protein every three weeks or four weeks after the first dose, wherein the second dose is greater than the first dose.

Abstract: The present disclosure provides an IL-6 formulation, comprising about 40 ?g/mL to about 2 mg/ml IL-6, about 5 to about 15 mM histidine, about 5 to about 15 mg/mL glycine, about 40 to about 60 mg/mL trehalose, about 0.1 to about 0.3 mg/mL polysorbate 20, and about 1 to about 1000 ?M DTPA, wherein the formulation has a pH of about 6.0 to about 8.0. Such formulations may be useful to treat and/or prevent a disease or disorder in a subject in need thereof.

Abstract: Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment. In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.

Abstract: The present disclosure provides a formulation of an IL-12-Albumin Binding Domain (ABD) fusion protein, comprising about 10 ?g/mL to about 50 ?g/mL fusion protein, about 25 mM to about 100 mM alanine, about 100 mM to about 400 mM trehalose, about 10 mM to about 50 mM glycylglycine, about 0.01% to about 0.04% polysorbate 20 (v/v), and about 5 ?M to about 20 ?M diethylenetriaminepentaacetic acid (DTPA), wherein the formulation has a pH of about 6.8 to about 8.0. Such formulations may be useful to treat and/or prevent IL-12 related diseases or disorders in a subject in need thereof.

Abstract: Provided herein are variant human IL-18 (hIL-18) proteins and fusion proteins comprising the variant hIL-18 proteins. Such variant hIL-18 proteins exhibit biological IL-18 activity while having reduced or no detectable binding to inhibitory IL-18BP. Thus, in some embodiments, the variant hIL-18 proteins advantageously retain IL-18 biological activity in the presence of IL-18BP. Such variant hIL-18 and related fusion proteins find use, for example, in the treatment of cancer.

Abstract: Provided herein are variant human IL-18 (hIL-18) proteins and fusion proteins comprising the variant hIL-18 proteins. Such variant hIL-18 proteins exhibit biological IL-18 activity while having reduced or no detectable binding to inhibitory IL-18BP. Thus, in some embodiments, the variant hIL-18 proteins advantageously retain IL-18 biological activity in the presence of IL-18BP. Such variant hIL-18 and related fusion proteins find use, for example, in the treatment of cancer.

Abstract: Provided herein are variant human IL-18 (hIL-18) proteins and fusion proteins comprising the variant hIL-18 proteins. Such variant hIL-18 proteins exhibit biological IL-18 activity while having reduced or no detectable binding to inhibitory IL-18BP. Thus, in some embodiments, the variant hIL-18 proteins advantageously retain IL-18 biological activity in the presence of IL-18BP. Such variant hIL-18 and related fusion proteins find use, for example, in the treatment of cancer.

Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.

Abstract: Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, in the anterior chamber of the eye and other ophthalmic wound healing. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.

Abstract: A purified thiol activated protease obtained from bromelain stem extract is provided. The protease has a molecular weight of about 17,000 daltons to about 21,000 daltons and an isoelectric point of about pI 4.5 to about pI 5.0. Methods for obtaining this enzyme and methods for use of this enzyme for debridement of eschar tissue are disclosed.

Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of human epidermal growth factor (EGF) and an amount of a pharmaceutically acceptable metal cation, such as zinc, which is sufficient to prevent the degradation of said EGF.